Recent approval under new international Project Orbis.
Ultra-rare, potentially life-threatening genetic disease.
Hemoglobin S Polymerization inhibitor oral treatment.
Approved for patients 18 years of age and older
Antibiotic with a novel penetrative mechanism.
Expected U.S. launch in 2023.
First and currently only biological targeting P-selectin.
MCL is an aggressive form of NHL
Shown to reduce regular RBC transfusions in adults with beta thalassemia.
Fourth filgrastim biosimilar from Sandoz, expected ASAP.